207 related articles for article (PubMed ID: 25032884)
1. Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update.
Arslan C; Dizdar O; Altundag K
Expert Opin Pharmacother; 2014 Aug; 15(12):1643-58. PubMed ID: 25032884
[TBL] [Abstract][Full Text] [Related]
2. Systemic treatment in breast-cancer patients with brain metastasis.
Arslan C; Dizdar O; Altundag K
Expert Opin Pharmacother; 2010 May; 11(7):1089-100. PubMed ID: 20345334
[TBL] [Abstract][Full Text] [Related]
3. Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
Zhang J; Zhang L; Yan Y; Li S; Xie L; Zhong W; Lv J; Zhang X; Bai Y; Cheng Z
Drug Metab Dispos; 2015 Mar; 43(3):411-7. PubMed ID: 25547867
[TBL] [Abstract][Full Text] [Related]
4. [Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Cao KI; Kirova YM
Cancer Radiother; 2014 Jun; 18(3):235-42; quiz 246, 249. PubMed ID: 24731405
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
Morikawa A; Peereboom DM; Thorsheim HR; Samala R; Balyan R; Murphy CG; Lockman PR; Simmons A; Weil RJ; Tabar V; Steeg PS; Smith QR; Seidman AD
Neuro Oncol; 2015 Feb; 17(2):289-95. PubMed ID: 25015089
[TBL] [Abstract][Full Text] [Related]
6. [Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies].
Bachelot T; Le Rhun E; Labidi-Gally I; Heudel P; Gilabert M; Bonneterre J; Pierga JY; Gonçalves A
Bull Cancer; 2013 Jan; 100(1):7-14. PubMed ID: 23305997
[TBL] [Abstract][Full Text] [Related]
7. Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts.
Bartolotti M; Franceschi E; Brandes AA
Future Oncol; 2013 Nov; 9(11):1653-64. PubMed ID: 24156325
[TBL] [Abstract][Full Text] [Related]
8. Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.
Abboud M; Saghir NS; Salame J; Geara FB
Breast J; 2010; 16(6):644-6. PubMed ID: 21070441
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
Lin NU; Diéras V; Paul D; Lossignol D; Christodoulou C; Stemmler HJ; Roché H; Liu MC; Greil R; Ciruelos E; Loibl S; Gori S; Wardley A; Yardley D; Brufsky A; Blum JL; Rubin SD; Dharan B; Steplewski K; Zembryki D; Oliva C; Roychowdhury D; Paoletti P; Winer EP
Clin Cancer Res; 2009 Feb; 15(4):1452-9. PubMed ID: 19228746
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.
Bergen ES; Berghoff AS; Rudas M; Preusser M; Bartsch R
Anticancer Drugs; 2015 Jun; 26(5):579-81. PubMed ID: 25714248
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
14. HER2-positive metastatic breast cancer: a changing scenario.
Mustacchi G; Biganzoli L; Pronzato P; Montemurro F; Dambrosio M; Minelli M; Molteni L; Scaltriti L
Crit Rev Oncol Hematol; 2015 Jul; 95(1):78-87. PubMed ID: 25748080
[TBL] [Abstract][Full Text] [Related]
15. Activity of T-DM1 in Her2-positive breast cancer brain metastases.
Bartsch R; Berghoff AS; Vogl U; Rudas M; Bergen E; Dubsky P; Dieckmann K; Pinker K; Bago-Horvath Z; Galid A; Oehler L; Zielinski CC; Gnant M; Steger GG; Preusser M
Clin Exp Metastasis; 2015 Oct; 32(7):729-37. PubMed ID: 26303828
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib in metastatic breast cancer.
Frenel JS; Bourbouloux E; Berton-Rigaud D; Sadot-Lebouvier S; Zanetti A; Campone M
Womens Health (Lond); 2009 Nov; 5(6):603-12. PubMed ID: 19863462
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
Lin NU; Freedman RA; Ramakrishna N; Younger J; Storniolo AM; Bellon JR; Come SE; Gelman RS; Harris GJ; Henderson MA; Macdonald SM; Mahadevan A; Eisenberg E; Ligibel JA; Mayer EL; Moy B; Eichler AF; Winer EP
Breast Cancer Res Treat; 2013 Nov; 142(2):405-14. PubMed ID: 24197661
[TBL] [Abstract][Full Text] [Related]
18. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
19. Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer.
Mutlu H; Büyükçelik A; Akça Z; Erden A
J Oncol Pharm Pract; 2015 Feb; 21(1):72-3. PubMed ID: 24154651
[TBL] [Abstract][Full Text] [Related]
20. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
